- Home
- LPTX vs RELL Comparison
LPTX vs RELL Comparison
Compare LPTX & RELL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- RELL
- Stock Information
- Founded
- LPTX 2011
- RELL 1947
- Country
- LPTX United States
- RELL United States
- Employees
- LPTX N/A
- RELL N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- RELL Electronic Components
- Sector
- LPTX Health Care
- RELL Technology
- Exchange
- LPTX Nasdaq
- RELL Nasdaq
- Market Cap
- LPTX 119.6M
- RELL 138.8M
- IPO Year
- LPTX N/A
- RELL N/A
- Fundamental
- Price
- LPTX $0.38
- RELL $8.91
- Analyst Decision
- LPTX Buy
- RELL
- Analyst Count
- LPTX 2
- RELL 0
- Target Price
- LPTX $8.00
- RELL N/A
- AVG Volume (30 Days)
- LPTX 321.1K
- RELL 38.7K
- Earning Date
- LPTX 08-11-2025
- RELL 07-23-2025
- Dividend Yield
- LPTX N/A
- RELL 2.69%
- EPS Growth
- LPTX N/A
- RELL N/A
- EPS
- LPTX N/A
- RELL N/A
- Revenue
- LPTX N/A
- RELL $204,394,000.00
- Revenue This Year
- LPTX N/A
- RELL $9.48
- Revenue Next Year
- LPTX N/A
- RELL $4.10
- P/E Ratio
- LPTX N/A
- RELL N/A
- Revenue Growth
- LPTX N/A
- RELL N/A
- 52 Week Low
- LPTX $0.22
- RELL $7.57
- 52 Week High
- LPTX $4.79
- RELL $15.51
- Technical
- Relative Strength Index (RSI)
- LPTX 46.09
- RELL 45.16
- Support Level
- LPTX $0.38
- RELL $8.86
- Resistance Level
- LPTX $0.44
- RELL $9.15
- Average True Range (ATR)
- LPTX 0.04
- RELL 0.28
- MACD
- LPTX -0.00
- RELL -0.02
- Stochastic Oscillator
- LPTX 22.52
- RELL 23.36
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About RELL Richardson Electronics Ltd.
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. Its products have applications in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. The company segments include PMT (Power and Microwave Technologies Group), Canvys, (Green Energy Solutions) GES, and Healthcare reportable segments. The company derives the majority of its revenues from the PMT segment.